BACE1 and Alzheimer disease: Indeed, our preclinical tests demonstrated that inhibition of PKCι/λ by auranofin, which targets its PB1 domain [62], significantly increases SORLA levels, disrupts the SORLA-βARR2 interaction, reduces BACE1-cleavage products and Aβ levels, and improves cognitive functions in AD model mice.